CRISPR‐interceded CHO cell line development approaches
Biotechnology and Bioengineering · 2023
DOI: 10.1002/bit.28329 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biotechnology and Bioengineering, 2023. Verfasst von Shahin Amiri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 171 Literaturangaben.
Abstract (Originalsprache)
For industrial production of recombinant protein biopharmaceuticals, Chinese hamster ovary (CHO) cells represent the most widely adopted host cell system, owing to their capacity to produce high‐quality biologics with human‐like posttranslational modifications. As opposed to random integration, targeted genome editing in genomic safe harbor sites has offered CHO cell line engineering a new perspective, ensuring production consistency in long‐term culture and high biotherapeutic expression levels. Corresponding the remarkable advancements in knowledge of CRISPR‐Cas systems, the use of CRISPR‐Cas technology along with the donor design strategies has been pushed into increasing novel scenarios in cell line engineering, allowing scientists to modify mammalian genomes such as CHO cell line quickly, readily, and efficiently. Depending on the strategies and production requirements, the gene of interest can also be incorporated at single or multiple loci. This review will give a gist of all the most fundamental recent advancements in CHO cell line development, such as different cell line engineering approaches along with donor design strategies for targeted integration of the desired construct into genomic hot spots, which could ultimately lead to the fast‐track product development process with consistent, improved product yield and quality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
- Department of Medical Biotechnology, School of Advanced Technologies, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Shahin Amiri, Setare Adibzadeh, Samaneh Ghanbari, Behnaz Rahmani, Mohammad H Kheirandish, Aref Farokhi-Fard, Mansoureh S Dastjerdeh, Fatemeh Davami
Zitieren
APA
Amiri, S., Adibzadeh, S., Ghanbari, S., Rahmani, B., Kheirandish, M. H., Farokhi-Fard, A., Dastjerdeh, M. S., & Davami, F. (2023). CRISPR‐interceded CHO cell line development approaches. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28329
Vancouver
Amiri S, Adibzadeh S, Ghanbari S, Rahmani B, Kheirandish MH, Farokhi-Fard A, et al. CRISPR‐interceded CHO cell line development approaches. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28329
BibTeX
@article{Amiri2023,
author = {Amiri, Shahin and Adibzadeh, Setare and Ghanbari, Samaneh and Rahmani, Behnaz and Kheirandish, Mohammad H and Farokhi-Fard, Aref and Dastjerdeh, Mansoureh S and Davami, Fatemeh},
title = {CRISPR‐interceded CHO cell line development approaches},
journal = {Biotechnology and Bioengineering},
year = {2023},
doi = {10.1002/bit.28329}
}
EUVIMED